Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019.

Clark, Kristina E N; Nevin, William D; Mahungu, Tabitha; Lachmann, Helen; Singh, Animesh

Clark, Kristina E N; Nevin, William D; Mahungu, Tabitha; Lachmann, Helen; Singh, Animesh.

Clark KEN; Department for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom.
Nevin WD; Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
Mahungu T; Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
Lachmann H; UK National Amyloidosis Centre, University College London, London, United Kingdom.
Singh A; Department of Rheumatology, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.

Clin Infect Dis ; 73(9): e3110-e3112, 2021 11 02.

Article in English | MEDLINE | ID: covidwho-1501010

ABSTRACT

ABSTRACT

The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.

Subject(s)

COVID-19; Lymphohistiocytosis, Hemophagocytic; Humans; Lymphohistiocytosis, Hemophagocytic/diagnosis; Risk Factors; SARS-CoV-2

Keywords

HLH; COVID-19; HScore; cytokine storm

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphohistiocytosis, Hemophagocytic / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google